Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tibet Pharma Plans to End Short Stint as Public Company

publication date: Feb 27, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tibet Pharma announced – almost in passing – that it wishes to go private, ending its short career as a public company. The Chairman of the company, Hong Yu, offered $3 per each share of Tibet Pharma, which is more than four times its previous closing price of $.72. That is an impressive premium, but for investors, the downside is that the company floated its IPO just 13 months ago at $5.50. More details....

Stock Symbol: (NSDQ: TBET)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...